FORMULATION AND CHARACTERISATION OF PLGA-DOXORUBICIN COMPOSITES CONJUGATED WITH BISPHOSPHONATES IN ONCOLOGICAL THERAPY

The study investigates the characteristics of PLGA-based particles encapsulating doxorubicin (Doxo) and functionalised with alendronate (Aln) for controlled drug delivery.Zeta potential measurements indicated moderate colloidal stability of both PLGA-Doxo and PLGA-Doxo-Aln particles, with values of -7 mV and -10 mV, respectively.This negative charge suggests weak electrostatic repulsion between particles, potentially promoting aggregation in complex biological environments.Numerical and volumetric distributions showed that most particles were in the 550 -822 nm size range, with a predominant particle size of 817.2 nm for PLGA-Doxo-Aln.The morphology of the particles revealed a porous structure, which could influence the gradual release of Doxo.Antibacterial activity tests showed significant inhibition of S. aureus by PLGA-Doxo, while PLGA-Doxo-Aln showed no activity against E. coli due to functionalization with Aln.Release studies indicated a controlled release of both Aln and Doxo, with gradual degradation of the PLGA matrix contributing to prolonged drug release.The results suggest that PLGA-Doxo-Aln particles could serve as a promising system for targeted drug delivery, particularly for bone-related cancers. RezumatStudiul investigheaz caracteristicile particulelor pe baz de PLGA care ncorporeaz doxorubicin (Doxo) i sunt funcionalizate cu alendronat (Aln) pentru cedarea controlat a substanelor medicamentoase.Msurtorile potenialului Zeta au indicat o stabilitate coloidal moderat a particulelor PLGA-Doxo i PLGA-Doxo-Aln, cu valori de -7 mV i -10 mV, respectiv.Aceast sarcin negativ sugereaz o repulsie electrostatic slab ntre particule, ceea ce ar putea favoriza agregarea acestora n medii biologice complexe.Distribuiile numerice i volumetrice au artat c majoritatea particulelor se ncadreaz n intervalul de dimensiuni 550 -822 nm, cu o dimensiune predominant a particulelor de 817,2 nm pentru PLGA-Doxo-Aln.Morfologia particulelor a relevat o structur poroas, care ar putea influena eliberarea treptat a Doxo.Testele de activitate antibacterian au artat o inhibare semnificativ a S. aureus de ctre PLGA-Doxo, n timp ce PLGA-Doxo-Aln nu a prezentat activitate mpotriva E. coli din cauza funcionalizrii cu Aln.Studiile de eliberare au indicat o eliberare controlat att a Aln, ct i a Doxo, cu degradarea treptat a matricei PLGA contribuind la eliberarea prelungit a medicamentului.Rezultatele sugereaz c particulele PLGA-Doxo-Aln ar putea reprezenta un sistem promitor pentru livrarea intit a medicamentelor, n special pentru cancerele osoase.